Another Aussie drug on the cards

Posted 13 December 2024 AM

NuNerve has become the latest homegrown biotech to announce promising results of a potential new treatment for amyotrophic lateral sclerosis (ALS) - the most common form of motor neurone disease (MND).

The University of Queensland spin-out company, which formed in 2009, published results in Clinical Drug Investigations that demonstrated highly promising signs of disease stabilisation and no significant safety issues with treatment of the candidate dubbed NUN-004.

To see the whole article, please login